Boston Scientific has priced a public offering of $1.85 billion aggregate principal amount of its senior notes.
Here are four takeaways:
1. The public offering consists of $600 million of 2.85 percent notes due May 15, 2020; $500 million of 3.375 percent notes due May 15, 2022 and $750 million of 3.85 percent notes due May 15, 2025.
2. The company expects to receive the net offering proceeds upon closing on May 12.
3. The company will use the net proceeds, along with borrowings under its $750 million five-year term loan facility, to purchase the American Medical Systems urology portfolio, among other things.
4. The AMS portfolio acquisition is expected to close in the third quarter of 2015.
More articles on GI/endoscopy:
Gastroenterology special issue: "You are what you eat"
Boston Scientific sales hit $1.77 billion in Q1: 5 things to know
GI physician leader to know: Dr. Lawrence Kosinski of Illinois Gastroenterology Group